Oreana Neonatal Screening Home Test Kit Buy Online

About Description

Testing for clinically actionable and highly penetrant mutations
Superior targeted genomic analysis, targeting all coding sequences of the tested genes
Results are reported quickly, to accommodate for timely and effective interventions
Results are reported quickly, to accommodate for timely and effective interventions
High sensitivity and specificity
High precision and accuracy
Non-invasive, painless and safe for the infant

Neonatal Screening Test (Oreana)

Regular price £385.00 ~~£425.00~~
Order within

To receive your order

Oreana Neonatal Screening can identify infants who are aected by a manageable or treatable disease soon after birth, before the onset of symptoms. The disorders tested could have detrimental effects on normal development, even leading to death. Most of these diseases have a vast array of symptoms once they manifest, making diagnosis lengthy and complicated. With timely detection, Oreana gives you the opportunity to take informed and early decisions on the best clinical management for your patient.

Oreana can also be used to identify genetic diseases in newborns, infants or children who present with a variety of clinical symptoms.

WHY RECOMMEND Oreana IN ADDITION TO NATIONAL NEWBORN SCREENING?

National newborn screening programs offer great advantages for infants, their families and national health systems. However, because they are subjected to each country's regulations, healthcare system and available funds, implementation of changes, such as the use of more advanced technology or the addition of clinically important diseases, can take time. As a result, the number of conditions tested is vastly different throughout Europe and the world; countries perform newborn screening ranging from only 2 disorders to over 35.

With Oreana neonatal screening, 106 conditions that are treatable or manageable can be detected before the appearance of clinical signs in asymptomatic newborns. With early interventions, irreversible damages to the infant can be limited or prevented, benefiting their quality of life. Additionally, accurate identification of disease-causing variants in symptomatic newborns can signify the start of beneficial, therapeutic treatment.